SIK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1147178	0.56	9/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	8/20
Dasatinib Anhydrous (SCHEMBL8226)	0.98	8/20
SCHEMBL1147002	0.52	8/20
SCHEMBL1147078	0.52	8/20
SCHEMBL1147168	0.53	7/20
SCHEMBL1146867	0.52	7/20
SCHEMBL41486	0.43	7/20
SCHEMBL791573	0.50	6/20
SCHEMBL774309	0.54	5/20
SCHEMBL792105	0.53	5/20
SCHEMBL1147167	0.52	5/20
SCHEMBL775128	0.45	5/20
Ucn-01 (SCHEMBL259162)	1.00	4/20
SCHEMBL1147156	0.82	4/20
SCHEMBL1147171	0.82	4/20
SCHEMBL1146496	0.80	4/20
SCHEMBL1147166	0.78	4/20
SCHEMBL1147163	0.76	4/20
SCHEMBL1146865	0.68	4/20

Clinical trials — most relevant to SIK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	PHASE2	UNKNOWN
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer	PHASE2	COMPLETED
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Biomarkers in Samples From Patients With Endometrial Cancer	nan	WITHDRAWN
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a SIK2 binder may also engage these)

Protein	Name	Similarity
Q8CFH6	—	0.999	Q8CFH6 →
Q5REX1	—	0.999	Q5REX1 →
Q6NSM8	—	0.994	Q6NSM8 →
Q6P4S6	—	0.993	Q6P4S6 →
Q60670	—	0.993	Q60670 →
SIK3	Serine/threonine-protein kinase SIK3	0.992	landscape →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.992	landscape →
A7MBB4	—	0.991	A7MBB4 →
P46200	—	0.991	P46200 →
P56931	—	0.991	P56931 →
P10244	—	0.991	P10244 →
Q3ULB5	—	0.991	Q3ULB5 →
BMP2K	BMP-2-inducible protein kinase	0.990	landscape →
Q9R1U5	—	0.990	Q9R1U5 →
Q76I79	—	0.990	Q76I79 →
Q5R8X7	—	0.989	Q5R8X7 →
Q5WM45	—	0.989	Q5WM45 →
Q4G112	—	0.989	Q4G112 →
Q8R4S7	—	0.989	Q8R4S7 →
Q14209	—	0.989	Q14209 →
Q32NH9	—	0.989	Q32NH9 →
Q68UT7	—	0.989	Q68UT7 →
Q63553	—	0.989	Q63553 →
Q6P0Q8	—	0.988	Q6P0Q8 →
Q9Z1J2	—	0.988	Q9Z1J2 →
Q9GZV8	—	0.988	Q9GZV8 →
Q8VII8	—	0.988	Q8VII8 →
Q641K5	—	0.988	Q641K5 →
Q1HKZ5	—	0.988	Q1HKZ5 →
Q3YC04	—	0.988	Q3YC04 →